Table 2.
Author | Year | Genotype | Total | Events | Detection rate |
---|---|---|---|---|---|
Tato [9] | 2016 | OXA-48 | 40 | 38 | 95% |
2016 | NDM | 26 | 26 | 100% | |
2016 | VIM | 31 | 29 | 93.55% | |
2016 | KPC | 30 | 29 | 96.67% | |
2016 | IMP | 27 | 26 | 96.30% | |
| |||||
McMullen [10] | 2017 | OXA-48 | 12 | 12 | 100% |
2017 | NDM | 27 | 27 | 100% | |
2017 | VIM | 7 | 7 | 100% | |
2017 | KPC | 84 | 84 | 100% | |
2017 | IMP | 1 | 1 | 100% | |
| |||||
Moore [11] | 2017 | OXA-48 | 113 | 111 | 98.23% |
2017 | NDM | 88 | 88 | 100% | |
2017 | VIM | 92 | 87 | 94.57% | |
2017 | KPC | 110 | 110 | 100% | |
2017 | IMP | 80 | 76 | 95% | |
| |||||
Findlay [14] | 2015 | OXA-48 | 100 | 100 | 100% |
2015 | NDM | 100 | 100 | 100% | |
2015 | VIM | 100 | 100 | 100% | |
2015 | KPC | 100 | 100 | 100% | |
2015 | IMP | 24 | 17 | 71% | |
| |||||
Hoyos-Mallecot [15] | 2017 | OXA-48 | 10 | 10 | 100% |
2017 | KPC | 1 | 1 | 100% | |
| |||||
Kost [16] | 2017 | OXA-48 | 9 | 8 | 88.90% |
2017 | NDM | 25 | 25 | 100% | |
2017 | VIM | 3 | 3 | 100% | |
2017 | KPC | 43 | 41 | 95.30% | |
2017 | IMP | 2 | 2 | 100% | |
| |||||
Vanstone [17] | 2018 | OXA-48 | 24 | 24 | 100% |
2018 | NDM | 22 | 22 | 100% | |
2018 | VIM | 19 | 19 | 100% | |
2018 | KPC | 3 | 3 | 100% | |
2018 | IMP | 1 | 1 | 100% | |
| |||||
Traczewski [18] | 2018 | OXA-48 | 89 | 89 | 100% |
2018 | NDM | 78 | 78 | 100% | |
2018 | VIM | 82 | 82 | 100% | |
2018 | KPC | 84 | 84 | 100% | |
2018 | IMP | 40 | 40 | 100% | |
| |||||
Cointe [19] | 2019 | OXA-48 | 10 | 10 | 100% |
2019 | NDM | 11 | 11 | 100% | |
2019 | VIM | 7 | 7 | 100% | |
2019 | KPC | 10 | 10 | 100% | |
2019 | IMP | 1 | 1 | 100% |